Expression Vectors Market Size, Share, Segmentation, Trends, and Forecast 2030

Table Of Content

Methodology

Free Analysis

The expression vector is also known as expression construct which is the basic tools in biotechnology for the production of proteins. E. coli is commonly used as the host for protein production. The expression vector is used in the production of insulin for medical treatments of diabetes. Virus vector, the bacterial vector, plasmid DNA and others are key types of vector system.

The major driving factor for the global expression vector market is the strong demand of protein-based drugs. Moreover, technological advancement in protein expression techniques, molecular biology, and bioinformatics is anticipated to drive the market demand in the years to come. Applications of expression vectors in the R&D of biomedical and biopharmaceutical products are expected to have the positive impact on expression vector market over the forecast period. However, high expenditure involved in research employing expression vectors may curb the market growth in the coming years. Nonetheless, large production of human insulin and other protein-based products that use expression vectors may open up new growth opportunities in the years to come.

On the basis of the host, the market can be segmented into bacterial, yeast, insect and mammalian. Bacterial vector was accounted for the major share of total expression vectors market in 2019 and expected to exhibit significant share within the forecast period. This is mainly due to high transformation levels and simple transformation protocols. The mammalian expression vector is expected to witness the fastest growth within the forecast period. Mammalian host systems have the ability to carry out assembly of recombinant proteins, folding, and complex post-translational modifications.

The expression vectors market is segmented on the basis of different applications such as therapeutic, industrial, and research applications. Therapeutic has dominated the market with the largest share of the total market in 2019.  This growth is mainly attributed to the higher incidence rate of oncology diseases which can be treated by use of expression vectors. Research segment is also accounted for the significant share due to technological advancement in proteomics and novel product development.

Some of the key end-users in expression vectors market include biotechnology & pharmaceutical companies, contract research organizations (CROS) & contract manufacturing organizations (CMOS) & academic research institutes. Biotechnology & pharmaceutical was the leading segment with the largest number of market share of total revenue generated in 2019 owing to advancement in novel drug and protein pharmaceuticals synthesis using recombinant DNA technology. Contract research organizations (CROs) & contract manufacturing organizations (CMOs) is expected to witness significant growth in the years to come.

North America was the leading regional market for expression vectors in 2019 due to increasing scientific research and development of novel technologies. Moreover, high investment of the U.S. private companies in biology R&D activities further expected to boost the expression vectors market in North America. North America is followed by Asia-Pacific and Europe in terms of revenue. Asia Pacific is expected to exhibit strong growth for expression vectors in the years to come. This growth is mainly attributed to increasing penetration of companies in R&D activities in biotechnology perspective.

Some of the key players including in the expression vectors market such as Clontech Laboratories, Inc., New England Biolabs, Sigma-Aldrich Corporation, Promega Corporation, Agilent Technologies, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Merck Millipore, QIAGEN, and GenScript USA Inc.